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Summary
Given the critical role that the immune system plays in a multitude of
diseases, having a clear understanding of the pharmacology of the
immune system is crucial to new drug discovery and development. Here
we describe the International Union of Basic and Clinical Pharmacology
(IUPHAR) Guide to Immunopharmacology (GtoImmuPdb), which con-
nects expert-curated pharmacology with key immunological concepts and
aims to put pharmacological data into the hands of immunologists. In the
pursuit of new therapeutics, pharmacological databases are a vital
resource to researchers through providing accurate information on the
fundamental science underlying drug action. This extension to the exist-
ing IUPHAR/British Pharmacological Society Guide to Pharmacology sup-
ports research into the development of drugs targeted at modulating
immune, inflammatory or infectious components of disease. To provide a
deeper context for how the resource can support research we show data
in GtoImmuPdb relating to a case study on the targeting of vascular
inflammation.
Keywords: database; immune-therapeutics; immunopharmacology;
pharmacology.
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Introduction
The immune system has become a major target for new
therapeutics, with approximately 20% of new drug
approvals in the last 5 years targeting elements of the
immune system (www.fda.gov/drugs/development-approval-
process-drugs/new-drugs-fda-cders-new-molecular-entities-
and-new-therapeutic-biological-products). A high propor-
tion of diseases are also associated with an immune or
inflammatory component or process. In particular, chronic
age-related diseases such as Alzheimer’s disease, atheroscle-
rosis and diabetes have inflammatory components.1–5 The
significant roles that inflammation and immune mecha-
nisms play in cardiovascular disease (CVD) have also made
them potential therapeutic targets in its treatment.6
Autoimmunity is a serious problem, for example in multi-
ple sclerosis,7,8 Sj€ogren’s syndrome,9 inflammatory bowel
disease10,11 and rheumatoid arthritis.12 Such conditions
may coexist with depressive disorders.13 There is also much
interest in the use of immune therapies, such as the poten-
tial exploitation of dendritic cells, to treat cancer.14,15
The International Union of Basic and Clinical Phar-
macology (IUPHAR) and the British Pharmacological
Society (BPS) collaborate on the development and
maintenance of the Guide to Pharmacology (GtoPdb,
www.guidetopharmacology.org). This database is an
expert-curated resource of ligand-activity-target relation-
ships, selected from high-quality pharmacological and
medicinal chemistry literature. It has its origins in
IUPHAR-DB and the BPS Guide to Receptors and
Channels, both of which focused on receptors and
channels.16–18 The scope of GtoPdb has expanded over
the years19–22 and a Wellcome Trust-funded project has
allowed us to address the priority area of immunity,
inflammation and infection.23–26 In the course of that
project, the database has expanded into the field of
immunopharmacology.21
Well-curated pharmacological databases are an impor-
tant foundation for research on new therapeutics. In the
context of immunopharmacology, although there are
good internet resources that support purely immunologi-
cal research, for example Immunopaedia (www.im
munopaedia.org.za), ImmPort (www.immport.org),
ImmGen (www.immgen.org), InnateBD (www.innatedb.c
om) and IMGT (www.imgt.org), none cover the
pharmacology of the immune system. The IUPHAR
Guide to Immunopharmacology (GtoImmuPdb; www.
guidetoimmunopharmacology.org) has been developed to
deliver a knowledge-base that, for the first time, connects
immunology with pharmacology.27 It expands the data
associated with targets and ligands to cover immunologi-
cal data types and enhances access to the pharmacological
data through a user interface tailored to the immunolo-
gist. GtoImmuPdb puts valuable pharmacological data
into an immunological context and is a resource that
enables researchers to easily identify pharmacological
agents that can be used experimentally to modulate
immune system mechanisms.
The IUPHAR/BPS Guide to Pharmacology
The Guide to Pharmacology holds data on nearly 3000
human proteins, with over 1700 of these ‘targets’ having
curated pharmacological interaction data. In total, the
database has information on over 9700 ligands, and it
contains quantitative data on over 14 000 ligand–target
interactions. The selection of content is supported through
the expertise of 96 target family subcommittees of the
Nomenclature Committee of IUPHAR (NC-IUPHAR),
comprising over 500 scientists worldwide. GtoPdb uses
expert human judgement at all stages of curation, in con-
trast to more automated data and text mining approaches.
Curation is not though limited to only the NC-IUPHAR
subcommittees; we also encourage users to make sugges-
tions about content, which when checked often results in
appropriate additions or qualifications.
The GtoPdb is a well-used and highly cited resource.
Our analytics show that the database is accessed by over
22 000 users worldwide each month and they generate a
total of more than 118 000 page views. We produce two
main biennial publications. The most prominent of these
is the Concise GtoPdb,28 which provides concise over-
views of the key properties of nearly 1800 human drug
targets with an emphasis on selective pharmacology. The
last two editions (2015/1629 and 2017/1830) combined
have over 2600 citations. We also produce a biennial
publication in Nucleic Acids Research (NAR) Database
Issue, which documents database and curatorial updates.
Our 201620 and 201821 papers have been cited over 1460
times.
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The IUPHAR Guide to Immunopharmacology:
development and curation
In establishing the GtoImmuPdb, NC-IUPHAR expert
subcommittees identified targets relevant to immunophar-
macology, and they provided detailed curatorial com-
ments on the reasons for their inclusion in the resource.
In the 2019.5 database release, 614 targets and 1232
ligands were tagged as relevant to immunopharmacology
(www.guidetoimmunopharmacology.org//immuno/immuno
HelpPage.jsp#gtoimmupdb_content).
Curating GtoImmuPdb data
The first phase of curation involved assessing protein tar-
gets and ligands that were already in the GtoPdb for
inclusion in the GtoImmuPdb. To extend coverage
beyond what was already in GtoPdb, we made use of the
Gene Ontology (GO) ‘biological process’ annotations to
prioritize targets for curation. We produced a draft list of
targets for inclusion in GtoImmuPdb on the basis of both
direct involvement in inflammation/immunity and based
on involvement in processes known to be important in
inflammation/immunity. Ligands for targets that qualified
for GtoImmuPdb were then reviewed and included if
there was evidence that their activity has a modulatory
effect on the inflammation/immune system (e.g. drugs
approved to treat inflammatory conditions, or tool com-
pounds used to investigate GtoImmuPdb targets). The
selection of content for curation was supported by the
NC-IUPHAR subcommittees, who identified key papers
and literature reviews. Examples of inclusions identified
at this stage are histamine receptors (www.guidetoim
munopharmacology.org/GRAC/FamilyDisplayForward?fa
milyId=33)31 and anti-histamine drugs, glucocorticoid
receptor (www.guidetoimmunopharmacology.org/GRAC/
ObjectDisplayForward?objectId=625)32 and anti-inflam-
matory glucocorticoid drugs, cyclooxygenase enzymes
(www.guidetoimmunopharmacology.org/GRAC/FamilyDis
playForward?familyId=269)33 and non-steroidal anti-in-
flammatory drugs, and pattern recognition, cytokine and
chemokine receptor families. Examples of new content
added during this phase include additional families of
pattern recognition receptors34 and immune checkpoint
proteins, and ligands and immune checkpoint inhibitors
(clinical and investigational) used in immuno-oncology.
Targets and ligands continue to be added to the
GtoImmuPdb as new evidence emerges. Ongoing updates
are driven by systematic searches of current literature
covering immunology and inflammation to identify lead
compounds, their molecular targets and pharmacological
data. Other useful resources include pharmaceutical com-
panies’ declared development programmes and selective
patent analysis that can be used to identify
pharmacological data in the absence of peer-reviewed
publications. Review of clinical trial registries, applica-
tions to the World Health Organization for new Interna-
tional Nonproprietary Names (INN) (which provide an
indication of developments in the immunity/inflamma-
tion/immuno-oncology fields), and monitoring new drug
approvals can all identify novel ligands, protein targets
and molecular mechanisms of action.
Immunological processes and cell types
The data on targets and ligands have been extended by
annotating these with immunological data. This means we
have made clear connections between immunological pro-
cesses, cell types and disease, and the targets and ligands
already in the database. We have made use of biological
ontologies because they provide an organized, hierarchical
and controlled vocabulary against which to annotate data.
Ontologies also provide unique accession numbers that
identify a particular term, and these are valuable in sup-
porting interoperability between data resources. In the
context of GtoImmuPdb, they are also useful in curating
protein targets to different categories and in enabling
inferred searching. We have used biological processes from
the GO35,36 (geneontology.org) and cell types from the
Cell Ontology37 (http://obofoundry.org/ontology/cl.html).
The GO is a hierarchical ontology that describes bio-
logical processes, including processes that operate in the
immune and inflammatory systems.38,39 GtoImmuPdb
uses top-level process categories, such as T cell (activa-
tion) or Cytokine production and signalling, underpinned
by GO immune and inflammatory process terms. In the
case of T-cell activation, this includes terms such as ‘T-
cell-mediated immunity (GO:0002456)’ and ‘regulation of
T-cell differentiation (GO:00045580)’.
The Cell Ontology is designed as a structured vocabu-
lary for cell types, from prokaryotes to mammals. In a
similar way, GtoImmuPdb uses top-level cell type cate-
gories, such as Mast cells, because of their relevance in
anti-allergic therapies,40 and Innate lymphoid cells, reflect-
ing the growing understanding of their role within the
innate immune system in the control of tissue homeosta-
sis, infection, inflammation, metabolic disease and can-
cer.41,42 The top-level categories are underpinned by Cell
Ontology terms, which in the case of Mast cells includes
the terms ‘mast cell (CL_0000097)’ and its children, ‘mu-
cosal type mast cell (CL_0000485)’ and ‘connective tissue
type mast cell (CL_0000484)’.
Table 1 shows associations between the top-level pro-
cesses and the number of human immunopharmacological
target proteins. The table also shows the number of human
target proteins relevant to immunopharmacology associ-
ated with the top-level cell types. More details of how data
have been curated can be found in our recent publication.21
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The IUPHAR Guide to Immunopharmacology:
accessing the data
The GtoImmuPdb portal allows researchers with a primar-
ily immunological background to find pathways, drugs
and targets using an interface built around an immuno-
logical perspective. Immunological processes, cell types,
pathways and diseases are centre-stage and connect to
search functions that prioritize immunologically relevant
pharmacological data. This provides rapid access to lists of
targets and ligands relevant to immunopharmacology or
allows the viewing of lists of targets and ligands associated
with immunological processes, cell types and diseases. In
this way, GtoImmuPdb equips immunologists with a
means to discover pharmacological agents that are useful
in their research and provides a foundation for developing
research into therapeutic modifiers of the immune system.
Navigating the database from a starting point of
immunological process of cell type
The database contains nearly 200 targets associated with
T-cell activation (Table 1). These can be easily accessed
via the processes panel on the GtoImmuPdb portal
(Fig. 1a). The targets are organized into sections, one for
each target class. Figure 2(b) shows how some cluster of
differentiation (CD) molecule targets are displayed in the
Other Protein Targets section. The GO terms annotated
to a target are shown in the third column of Fig. 1(b);
summarized curatorial comments are also displayed. In
the example of CD28, its role in the activation, prolifera-
tion and survival of T cells is indicated. By clicking on
the target name, users can view the detailed targets page,
which contains the expanded curators’ comments and full
pharmacological information on the target.
The annotation of targets to cell types helps to high-
light useful pharmacological data relevant to
immunopharmacology. For example, the role of natural
killer cells in anti-tumour immunity is well estab-
lished,43,44 and the heterodimer CD94/NKG2A is known
to have a role in recognition of the main type of human
leucocyte antigen class I molecules and functions as a true
checkpoint in natural killer cell activation.45 NKG2A
(GtoPdb Target 2849; CD159a) is annotated in GtoIm-
muPdb as being expressed by cells in the natural killer
cells category, with the immunopharmacology commen-
tary highlighting its role as an inhibitory checkpoint
receptor for human leucocyte antigen E. The detailed
view for CD159a (www.guidetoimmunopharmacology.
org/GRAC/ObjectDisplayForward?objectId=2849#Antibo
dies) shows interaction data for the antibody monal-
izumab (www.guidetoimmunopharmacology.org/GRAC/
LigandDisplayForward?tab=summary&ligandId=8323), an
anti-NKG2A clinical lead molecule that is being devel-
oped for solid and haematological cancers (Fig. 2).
Ligand summaries
For ligands, the database contains key information on the
biological activity, clinical use, molecular properties,
structure and immunopharmacology. These data are dis-
played on the ligand summary pages, which are easily
accessed, either from the Ligands menu bar item, or the
Ligands panel on the home page (Fig. 3a). Different cate-
gories of ligand can be selected from tabs at the top of
the page. When navigating from the GtoImmuPdb portal,
the lists contain ligands tagged in the database as relevant
to immunopharmacology. Selecting a ligand links through
to the ligand summary page where data are organized
under several tabs (Fig. 3b). The Immunopharmacology
tab contains curator comments on a compound’s rele-
vance to immunopharmacology, as well as listing any dis-
ease associations. The Summary tab gives general
information about the compound, including if the drug
is approved for clinical use, and provides a list of trade
names (when used clinically), synonyms (such as preclini-
cal names) and INN so that the drug can be identified
and tracked in the literature. The ‘Biological Activity’ tab
as well as displaying tables of the ligand selectivity at tar-
gets in the database also provides access to the Ligand
Activity Visualization Tool (Fig. 3c). This tool provides
box plots summarizing all the activity data for a ligand
taken from ChEMBL46 and GtoPdb across multiple spe-
cies. The Clinical data tab provides information about
Table 1. GtoImmuPdb Process and Cell Type categories and the
number of human proteins associated with each group
Process
Annotated
human
targets Cell type
Annotated
human
targets
Barrier integrity 49 B cells 51
Inflammation 633 Dendritic cells 41
Antigen
presentation
142 Granulocytes 46
T cell (activation) 196 Innate
lymphoid
cells
6
B cell (activation) 161 Macrophages 56
Immune
regulation
503 Mast cells 39
Tissue repair 19 Natural killer
cells
26
Immune system
development
251 Other T cells 3
Cytokine
production and
signalling
504 Stromal cells 1
Chemotaxis and
migration
256 T cells 76
Cellular signalling 476
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molecular mechanisms of action and clinical trials
together with trial identifying numbers.
Disease summaries
The extension for immunopharmacology has also priori-
tized the development of pages that give consolidated
pharmacological summaries for different diseases. In all,
there are over 1000 diseases in the GtoPdb that have
curated associations with targets and/or ligands. The dis-
ease lists, accessed from the portal or menu bar, summa-
rize these (www.guidetoimmunopharmacology.org/GRAC/
DiseaseListForward?type=Immuno). As a consequence of
our recent curatorial focus on immunological data, dis-
eases with significant immunological aspects, such as
asthma, rheumatoid arthritis, inflammatory bowel and
psoriasis, show the greatest number of associations with
targets and/or ligands.
The disease summary pages show targets and ligands
associated with a disease and include links to Online
Mendelian Inheritance in Man47,48 (omim.org), Orphanet
(orpha.net) and the Disease Ontology49 (disease-ontology.
org), providing cross-references between the diseases in
GtoImmuPdb and other resources (www.guidetoim
munopharmacology.org/GRAC/DiseaseListForward?type=
Immuno). The pages also detail the bioactivities and clin-
ical uses of relevant ligands. For example, chronic lym-
phocytic leukaemia (www.guidetopharmacology.org/
GRAC/DiseaseDisplayForward?diseaseId=218; Fig. 4)
highlights CD20 as being the molecular target of four
antibodies: ofatumumab, veltuzumab, rituximab and
obinutuzumab. The summarized view shows these anti-
bodies listed against their molecular target and combines
this with detailed disease, clinical use and bioactivity
comments (Fig. 4). In the case of rituximab, the pages
not only explain its role in treating CD20-positive non-
Hodgkin’s lymphoma and chronic lymphocytic leukae-
mia, but highlight its role in several other autoimmune
conditions and in the suppression of antibody-mediated
organ rejection.50,51
Immunopaedia
Through the partnership between IUPHAR and the Inter-
national Union of Immunological Sciences (IUIS) to cre-
ate standard tools and nomenclature (https://iuis.org/ne
ws/2018-iuis-council-meeting-summary/), GtoImmuPdb
has been working in collaboration with the IUIS resource,
Immunopaedia (www.immunopaedia.org.za). Immuno-
paedia provides materials for teaching and learning
immunology, from the basic immune system to advanced
immunology and specialized focus areas. They are an offi-
cial provider for online resources for the IUIS, creating
and hosting online courses to educate and support partic-
ipants before and after immunology conferences world-
wide. We have undertaken to provide links from key
ligands in GtoImmuPdb to the rich and detailed clinical
case studies hosted by Immunopaedia (Fig. 5).
Figure 1. Browsing for targets associated with an immunological process. The GtoImmuPdb portal is shown in (a), with the Processes panel link-
ing to lists of targets associated with T-cell activation (b). Under the Other Proteins section (c) cluster of differentiation (CD) molecule targets
are listed, and in the example of CD28, curatorial comments indicate its role in the activation, proliferation and survival of T cells.
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Searching, web services and PubChem
The search mechanisms across the website have been
extended, such that the new immunological data types
are incorporated. The search algorithm itself has been
tailored so that when using the GtoImmuPdb URL,
results of immunological relevance are upweighted. The
immunological relevance of a target or ligand is deter-
mined by the amount of immunological data associated
with it in the database. Our application programming
interface has also been extended to incorporate parame-
ters to retrieve immunopharmacology tagged data.
The GtoPdb maintains strong connectivity with Pub-
Chem, the open chemistry database at the National
Institutes of Health.52 On each database release of
GtoPdb, we submit our chemical structures to Pub-
Chem. As part of this process, we include Depositor
Comments in the substance records that we submit to
PubChem. These comments, among other things, indi-
cate if a structure is part of GtoImmuPdb and contains
any immunopharmacology curatorial comments.
Described in more detail in our most recent NAR
paper,22 the inclusion of these comments in our Pub-
Chem submissions make it possible to run domain-
specific queries related to immunopharmacology when
searching via PubChem.
Case study: targeting vascular inflammation
The best way to illustrate the potential usefulness of
GtoImmuPdb is through a case study. We have chosen
vascular inflammation, because in the last three
decades, experimental data have clearly shown the cau-
sal role played by immune and inflammatory responses
in the initiation and development of atherosclerosis,
and in the regulation of plaque instability.6 Epidemio-
logical studies have also called attention to vascular
inflammation. To date, however, there is no
immunomodulatory treatment in routine use for pre-
vention of atherosclerosis.53 How might GtoImmuPdb
help to change this?
The Canakinumab Anti-inflammatory Thrombosis Out-
comes Study (CANTOS; http://clinicaltrials.gov/ct2/show/
Figure 2. Pharmacological data associated with an immunological cell type. The example shows linking from the portal via the cell type category
of Natural killer (NK) cells. The resulting list of targets associated with NK cells includes CD159a. Selecting the link through to the detailed view
page shows CD159a interaction with the antibody monalizumab, an anti-NKG2A clinical lead for haematological cancer.
ª 2020 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 160, 10–23 15
The IUPHAR Guide to Immunopharmacology
NCT01327846)53,54 has been the first large (>10 000),
randomized, double-blind, placebo-controlled trial to tar-
get the inflammatory cytokine interleukin, interleukin-1b
(IL-1b) (www.guidetoimmunopharmacology.org/GRAC/
LigandDisplayForward?tab=biology&ligandId=4974) for
secondary prevention (to reduce the number of new or
severe cases of the disease) of atherosclerosis. In CAN-
TOS, the human monoclonal antibody canakinumab
(www.guidetoimmunopharmacology.org/GRAC/LigandDis
playForward?tab=immuno&ligandId=6773) significantly
reduced the rate of a composite end-point of major car-
diovascular events in patients previously affected by
myocardial infarction (MI) and who had high levels of C-
reactive protein (CRP).53 The CANTOS trial represents
the first clinical evidence that targeting inflammation may
be a viable approach in atherosclerosis and it started an
important discussion on how to target vascular immune-
inflammatory responses in the most efficient way (which
might not be by targeting IL-1b).
The CANTOS was followed by the Cardiovascular
Inflammation Reduction Trial (CIRT; http://clinicaltria
ls.gov/ct2/show/NCT01594333).54,55 In CIRT, treatment
with low-dose methotrexate failed to reduce cardiovascu-
lar event rates in patients with previous multi-vessel
coronary artery disease or MI also affected by metabolic
syndrome or type 2 diabetes.55 It should be noted that
despite co-morbidities, CIRT patients had normal CRP
levels and therefore had not been selected on the basis
of residual inflammatory risk. Given that high levels of
CRP are associated with an increased risk of cardiovas-
cular events, this may help to explain the difference
between the CANTOS and CIRT results. In fact, in post
hoc observations within CANTOS, patients with the lar-
gest reduction in IL-6 and CRP in response to IL-1b
inhibition56 showed the greatest reduction in cardiovas-
cular mortality, whereas methotrexate had no effect on
circulating inflammatory mediators in CIRT. It is worth
noting that typing the name of a clinical trial into the
main search box on GtoImmuPdb returns a list of
ligands involved in the trial, where these data have been
curated.
We have learned to a great extent from both trials, but
we still have a long way to go before anti-inflammatory
therapies become standard care in the treatment of
CVD.57
Canakinumab is an expensive agent and it is very unli-
kely that it will be used in CVD prevention. Several fur-
ther directions may be investigated, and the first clear
opportunity is represented by the targeting of mediators
that sit either just above or below IL-1b. More recent
analysis from the CANTOS trial revealed that there
remains substantial residual inflammatory risk related to
both IL-18 and IL-6 after IL-1b inhibition.58 Therefore,
targeting IL-18 or IL-6 signalling59 could be a way for-
ward. These present us with several questions – can we
find a good way to target IL-18 or IL-6? Can GtoIm-
muPdb help in finding a good way to modulate either of
these molecules?
Figure 3. Ligand summary pages. (a) List of ligands is accessed from the menu bar. (b) clicking on a ligand name links to the ligand summary
page, here showing dupilumab. Data are presented under several tabs, including one specific to immunopharmacology. Users can link through to
the ligand activity visualization tool (c), to compare activities across species.
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Accessing ligand summaries for IL-6 and IL-18
To access information about IL-6 in GtoImmuPdb, go to
the portal and type IL-6 into the database search at the
top of any page. IL-6 is the top-hit from this search and
clicking on the ligand name links through to its ligand
summary page. Ligand summary pages can also be
accessed by browsing via the Ligand menu bar item, either
via Ligand List (alphabetical; Fig. 1), or Ligand Families,
which has several groupings of ligands, including one for
interleukins, where IL-6 can be found (Fig. 6).
Information on IL-6 is contained under several tabs on
the ligand summary page (Fig. 7). Figure 7(a) shows
information under the immunopharmacology tab, high-
lighting its pro-inflammatory and anti-inflammatory
effects and indicating its role in the treatment of rheuma-
toid arthritis. Figure 7(b) shows biological activity data,
which list ligands with which IL-6 interacts, including
binding affinity data and indications of whether the
ligands are approved drugs, as is the case for siltuximab.
As a starting point when considering a way to potentially
Figure 4. An example disease summary page illustrating chronic lymphocytic leukaemia (CLL; www.guidetopharmacology.org/GRAC/DiseaseDis
playForward?diseaseId=218). Four antibodies are highlighted, all of which are therapeutics for CLL, that target CD20. The ligands section pro-
vides extended curatorial commentary on the clinical use and bioactivity of the compounds.
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Figure 5. Example of ligand summary page links to relevant Immunopaedia clinical case studies. The illustrated link shows that the antibody
rituximab was used in the chemotherapy treatment of a case of lymphadenopathy.
Figure 6. Illustrates accessing ligand summary data using interleukin-6 (IL-6) as an example. Browsing via the menu bar for ligand families,
selecting the Interleukins group, opens the link through to the Interleukins group. Users can then link through from these points to the IL-6
ligand summary page (Fig. 7).
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target IL-6, these pharmacological data and immunologi-
cal context are helpful. They show that IL-6 is already a
validated drug target and a primary target of three ligands
including the approved drug siltuximab.
Similarly, information on IL-18 can be accessed in the
same way. Figure 8 shows some of the highlights from
the IL-18 ligand summary page, including tadekinig a, a
peptide ligand that binds to and inhibits the pro-inflam-
matory activity of IL-18 and has US Food and Drug
Administration orphan drug designation for the treat-
ment of macrophage activation syndrome. This is useful
pharmacological information and context for further
investigation of targeting IL-18.
Accessing immunopharmacology data for NLRP3 and
PCSK9
Targeting nucleotide-binding and oligomerization domain
(NOD) -like receptor family 3 (NLRP3) inflammasome
inhibitors that can inhibit both IL-1b and IL-1860 may
also present a viable way forward. In this regard, using
GtoImmuPdb to view the detailed target page for NLRP3
may be helpful. It is possible to use the direct search to
find NLRP3, but it can also be found by browsing
through the Catalytic Receptors targets, where NLRP334
is found under the pattern recognition receptors and
NOD-like receptor subfamilies. Figure 9 shows inhibitors
Figure 7. Highlights from the interleukin-6 (IL-6) ligand summary page (www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?li
gandId=4998). Curator’s comments (a) are shown under the immunopharmacology tab and indicate links with rheumatoid arthritis. Parts of the
biological activity tab (b), show ligands that interact with IL-6, including the approved drug siltuximab.
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and immunopharmacology comments from the NLRP3
detailed target page. Two of the three ligands, CY-09
and MCC950, have quantitative interaction data for
NLRP3 and all three are indicated as having relevance
to immunopharmacology. CY-09 and MCC950 (www.
guidetoimmunopharmacology.org/GRAC/LigandDisplay
Forward?tab=immuno&ligandId=10057#immuno) are
shown to have significant therapeutic effects in NLRP3-
driven diseases,61 MCC950 (www.guidetoimmunophar
macology.org/GRAC/LigandDisplayForward?tab=immuno&
ligandId=8228#immuno) has the potential to block
NLRP3-induced events and there is evidence that dapan-
sutrile (www.guidetoimmunopharmacology.org/GRAC/
LigandDisplayForward?tab=immuno&ligandId=10056) is
Figure 8. Showing the biological activity and immunopharmacology data from the interleukin-18 (IL-18) ligand summary page (www.guidetoim
munopharmacology.org/GRAC/LigandDisplayForward?ligandId=4983). Interaction with the tadekinig a peptide is highlighted, which plays a role
in reducing the inflammatory effect of IL-18.
Figure 9. Inhibitors and immunopharmacology data from the detailed target page for NRLP3 (www.guidetoimmunopharmacology.org/GRAC/Ob
jectDisplayForward?objectId=1770#Inhibitors). Immunopharmacology comments highlight its role in the regulation of inflammation. Both CY-09
and MCC950 have quantitative interaction data and these are marked with the immuno-icon, showing that they have relevance to immunophar-
macology.
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a clinical lead for autoinflammatory disease and heart
failure.
A further translational direction may be the develop-
ment of a novel combination of lipid-lowering and anti-
inflammatory treatments by design of monoclonal anti-
bodies that could simultaneously inhibit proprotein con-
vertase subtilisin/kexin type 9 (PCSK9; Fig. 10) and either
IL-1b or IL-6. Figure 10 shows inhibitor data from the
GtoImmuPdb for PCSK9, showing three monoclonal
antibodies with quantitative interaction data for PCSK9.
Both evolocumab and alirocumab are approved drugs,
and bococizumab is being evaluated in Phase III clinical
trials.
Another alternative in targeting the IL-1b pathway
could be targeting the IL-1 receptor itself, or modulating
signal transduction downstream of the activated receptors
such as members of the IL-1 receptor-associated kinase
(IRAK) family. In GtoImmuPdb, details for the IL-1
receptor (www.guidetopharmacology.org/GRAC/ObjectDis
playForward?objectId=1905) show that it is already tar-
geted by the antagonist peptide mimic anakira (www.
guidetopharmacology.org/GRAC/LigandDisplayForward?
tab=clinical&ligandId=6972). For IRAK4, the target detail
page shows 11 inhibitors (www.guidetopharmacology.org/
GRAC/ObjectDisplayForward?objectId=2045&familyId=
579&familyType=ENZYME#Inhibitors), six of which are
selective, including the Pfizer compound (PF-06650833;
www.guidetopharmacology.org/GRAC/LigandDisplayFor
ward?ligandId=9667) which is a clinical lead for rheuma-
toid arthritis, demonstrating that IRAK4 is a druggable
target in the pathway.
The testing of new drugs should move in parallel with
the identification of better biomarkers for patient stratifica-
tion, the development of novel molecular imaging
modalities for diagnosis and monitoring of vascular inflam-
mation, as well as novel drug-delivery systems for selective
in situ targeting of vascular immune pathways and conse-
quent reduced risk of systemic immunosuppression.62
Concluding remarks
The recent appreciation that most chronic diseases
include immune aspects, and that modulation of immu-
nity can have a profound effect on disease progression or
resolution, makes the immune system a critical target for
new therapies. The historically small overlap between
immunological and pharmacological research communi-
ties has probably hindered the rapid development of
immunologically relevant therapeutics. The IUPHAR
GtoImmuPdb database and search tools provide a partial
solution to this problem, allowing researchers with
immunological training to use search terms framed in the
concepts of immunology to find pharmacological infor-
mation and tools relevant to them. In this way, the data-
base should accelerate discovery and development of new
strategies against chronic disease.
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